9月30日，伟思医疗举办2025年半年度业绩说明会。会上管理层提到，公司现阶段研发领域发展规划如 下： 磁刺激领域: 聚焦精准神经调控技术研发，依托经颅磁刺激技术平台，深化抑郁症、焦虑症等精神心理 疾病的靶向治疗方案研究；同步推进国际化战略布局，加速盆底磁、塑形磁、经颅磁的海外注册； 电刺激领域: 以临床需求为导向，完成电刺激产品技术的迭代升级，重点开发支持多模块自由组合的智 能电刺激系统，整合生物反馈技术，实现下一代电刺激产品的全面取证上市，拓展其在神经康复、疼痛 管理等领域的应用场景。 电生理和康复机器人等领域：推进脑电结合智能康复机器人备以及康复专用经颅磁联合方案在康复市场 的应用与探索。 激光射频等其他能量源设备领域：扩大皮秒激光的适应证范围，完成皮秒激光产品的规模化量产；推进 脉冲光产品开发进展，构建覆盖面部皮肤治疗的多层次产品矩阵。 有投资者询问公司如何应对康复医疗设备行业增速波动。管理层表示，公司对大康复行业的发展前景充 满信心，相信其未来潜力巨大。康复服务模式也正多元化发展，从医院向社区和家庭延伸，多学科融合 趋势显著，为行业发展注入新动力。 基于此，公司将加大对大康复产业的营销推广和产品营销 ...

Core Viewpoint - The company is focusing on enhancing its core business segments, particularly in the fields of mental rehabilitation, pelvic floor rehabilitation, neurological rehabilitation, and medical aesthetics, aiming for growth and market share expansion in 2025 [2][3][4][5]. Business Segment Overview - **Mental Rehabilitation**: The company plans to leverage the MagNeuro ONE series products to increase market share and solidify its leading position in non-invasive neuroregulation [2]. - **Pelvic Floor Rehabilitation**: The company anticipates a stabilization in this segment through product iteration and transformation, with the high-frequency electrosurgical device becoming a new growth point [2]. - **Neurological Rehabilitation**: The company sees potential for growth due to low market share and plans to expand product categories and marketing efforts to enhance business scale [2]. - **Medical Aesthetics**: The company aims to enter the mainstream skin management market in 2025, focusing on a product matrix that includes skin, body, and intimate health solutions [2][4]. Policy Impact - The recent issuance of guidelines by the National Medical Insurance Administration for pricing in the neurotechnology sector is expected to support the company's investments in brain-computer interface technologies [3]. Women's Health Initiatives - The company is committed to expanding its product offerings in women's health, particularly in pelvic floor recovery, and aims to meet diverse health management needs throughout women's life cycles [4]. AI Integration - The company is actively integrating AI technologies into its product designs to enhance automation and intelligence, with applications in various therapeutic devices [7]. Rehabilitation Robotics - The company has developed a comprehensive range of rehabilitation robots that cater to various rehabilitation needs, focusing on intelligent and standardized solutions to improve recovery efficiency [8]. Silver Economy Strategy - The company is strategically positioned to benefit from the growing demand for rehabilitation services due to an aging population, with a diverse product matrix aimed at addressing the needs of elderly patients [9]. Financial Performance - The company reported a main revenue of 292 million yuan in Q3 2024, a year-on-year decrease of 12.06%, with a net profit of 78.17 million yuan, down 23.13% [14]. Market Ratings - Recent ratings from three institutions indicate a positive outlook, with two buy ratings and one hold rating, and a target price of 33.00 yuan [15]. Investment and M&A Plans - The company is exploring opportunities for external growth through mergers and acquisitions, particularly in related industry sectors, while maintaining a focus on internal growth [13].